The city states that every entity purchasing insulin has been directly harmed by this scheme, as the purchase price for every diabetes medication is derived from a false list price. Meriden is seeking both injunctive relief to stop the alleged scheme and damages for the harm caused. They are also seeking attorney fees in connection with the lawsuit.
A spokesperson for Novo Nordisk told Law360 on Tuesday that the company believes the allegations against it are meritless. A representative from CVS Health also denied the allegations, calling the city’s lawsuit “baseless” and stating that “pharmaceutical companies alone are responsible for the prices they set in the marketplace for the products they manufacture.” The representative went on to say that nothing in CVS’s agreements prevents drug manufacturers from lowering insulin prices and expressed support for such actions.
Eli Lilly responded by emphasizing its ongoing efforts to lower insulin prices and dismissed the lawsuit as baseless. The company pointed out that in previous cases regarding insulin pricing, plaintiffs had either dropped their claims, lost motions to proceed as a class action, or settled without receiving money. According to Eli Lilly, the outcomes of these cases speak for themselves.
